Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLEB001 for steroid-refractory acute graft-versus-host disease
ChiCTR2000035740Phase 2Completed
- Sponsor
- The First Medical Center of Chinese PLA General Hospital
- Start
- Aug 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amimestrocel in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by The First Medical Center of Chinese PLA General Hospital. Primary endpoint: Overall response rate at Day 28. Started Aug 2020; status: completed.
02
Drugs
amimestrocel
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on ChiCTR2000035740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035740.